Physician profile
Hannah Son
NPI 1114774130
$7,847.25
in general payments reported to CMS, 2019-2025
53 companies · $5,201 in 2025
The $5,201 reported for 2025 was more than what 98% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $2,646 · 2025: $5,201.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,209 · Education: $638.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,209.34 |
| Education | $637.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $488.11 | 2024-2025 | |
| Incyte Corporation | $457.25 | 2024-2025 | Jakafi, Monjuvi, Zynyz |
| Janssen Biotech, INC. | $403.91 | 2024-2025 | Rybrevant, Talvey, Tecvayli |
| Takeda Pharmaceuticals U.S.A., INC. | $387.85 | 2024-2025 | Fruzaqla, Ninlaro, Iclusig |
| Merck Sharp & Dohme LLC | $363.56 | 2024-2025 | Keytruda, Welireg, Lynparza |
| Daiichi Sankyo INC. | $363.03 | 2024-2025 | Enhertu, Datroway, Vanflyta |
| Puma Biotechnology, INC. | $360.36 | 2024-2025 | |
| Eisai INC. | $335.31 | 2024-2025 | |
| Abbvie INC. | $277.45 | 2024-2025 | |
| Astellas Pharma US INC | $259.24 | 2024-2025 | Vyloy, Xospata, Padcev |
| Sobi, INC | $251.05 | 2024-2025 | |
| Gilead Sciences, INC. | $233.47 | 2024-2025 | Trodelvy |
| Pfizer INC. | $211.65 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $208.39 | 2024-2025 | Enhertu, Imfinzi |
| Genentech USA, INC. | $197.35 | 2024-2025 | Itovebi, Tecentriq, Phesgo |
Show all 53 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $196.84 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $187.10 | 2025 | Opdivo, Opdualag |
| Beone Medicines USA, INC. | $185.42 | 2025 | Brukinsa, Tevimbra |
| Karyopharm Therapeutics INC. | $181.65 | 2024-2025 | Xpovio |
| Array Biopharma INC | $166.45 | 2024-2025 | Mektovi, Braftovi, Tukysa |
| Exelixis INC. | $160.93 | 2024-2025 | Cabometyx |
| Lilly USA, LLC | $147.23 | 2024-2025 | Jaypirca, Verzenio |
| Stemline Therapeutics INC. | $145.80 | 2024-2025 | Orserdu, Elzonris |
| Deciphera Pharmaceuticals INC. | $121.33 | 2024-2025 | Qinlock, Tgct |
| Boehringer Ingelheim Pharmaceuticals, INC. | $118.79 | 2024-2025 | Gilotrif |
| Ipsen Biopharmaceuticals, INC | $112.44 | 2024-2025 | Onivyde, Somatuline Depot |
| Glaxosmithkline, LLC. | $104.76 | 2024-2025 | Jemperli, Zejula, Ojjaara |
| Iovance Biotherapeutics, INC. | $100.58 | 2025 | Amtagvi |
| Taiho Oncology, INC. | $96.87 | 2024-2025 | |
| Beigene USA, INC. | $92.74 | 2024-2025 | Brukinsa |
| Emd Serono, INC. | $86.67 | 2024-2025 | |
| Blueprint Medicines Corporation | $85.92 | 2024-2025 | Ayvakit |
| Genmab U.S., INC. | $85.31 | 2024-2025 | Epkinly |
| Novocure INC. | $66.57 | 2025 | Optune Lua (Novottf-200t), Optune Gio |
| Aveo Pharmaceuticals, INC. | $66.32 | 2025 | |
| Rigel Pharmaceuticals, INC. | $64.65 | 2024-2025 | Rezlidhia, Tavalisse, Gavreto |
| Pharmacosmos Therapeutics INC. | $48.73 | 2024-2025 | Monoferric, Cosela |
| Genzyme Corporation | $48.41 | 2025 | |
| Ge Healthcare | $38.87 | 2025 | |
| Jazz Pharmaceuticals INC. | $32.99 | 2025 | |
| Azurity Pharmaceuticals, INC. | $31.07 | 2025 | Danziten |
| Caris Mpi, INC. | $29.34 | 2025 | Mi Cancer Seek |
| Octapharma USA, INC. | $28.43 | 2025 | Octagam Immune Globulin (Human) |
| Alexion Pharmaceuticals, INC. | $27.88 | 2025 | Ultomiris |
| Agios Pharmaceuticals, INC. | $26.69 | 2025 | Pyrukynd |
| Celgene Corporation | $26.39 | 2024 | Reblozyl |
| Kyowa Kirin, INC. | $25.18 | 2025 | |
| Tolmar, INC. | $25.14 | 2024 | |
| Syndax Pharmaceuticals, INC. | $20.55 | 2025 | |
| Helsinn Therapeutics (U.S.), INC. | $18.07 | 2025 | Akynzeo |
| Verity Pharmaceuticals INC. | $17.23 | 2025 | Trelstar |
| Immunocore Limited | $15.67 | 2025 | Kimmtrak |
| Pharmaessentia USA Corporation | $14.26 | 2025 | Besremi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hannah Son listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.